INTRODUCTION: @entity1499 ( @entity1500 ) is an antineoplastic agent widely used in low dose to treat @entity1 with @entity309 ( @entity309 ). Its side effects can partly be explained by @entity1501 antagonism. @entity4181 ( @entity4181 ) is generally administered with @entity1500 to decrease @entity1500 -induced @entity137 . However information regarding the inhibitory effect of @entity4181 against cytogenetic damage caused by @entity1500 is limited. The aim of this study was to assess the protective effect of @entity4181 against @entity1500 -genotoxicity. METHODS: This study was done on @entity35 albino @entity35 and in @entity1 with @entity309 . Forty @entity35 of both sexes were randomized into four equal groups and dosed in the following way: Group-I, distilled water vehicle; Group-II, 0.5 mg/kg @entity4181 ; Group-III, 0.5 mg/kg @entity1500 ; Group-IV, 0.5 mg/kg @entity4181 plus 0.5 mg/kg @entity1500 . Doses were given i.p., once daily for 8 consecutive days. A bone marrow chromosomal study and a micronucleus test were performed for each @entity35 . Twenty @entity1 with @entity309 (5 males and 15 females) on a 10 mg weekly dose of @entity1500 , i.m., for one month, were administered the same dose of @entity1500 in addition to 10 mg of @entity4181 as a single dose 4 hours after @entity1500 administration, i.m., every week for another 4 weeks. Chromosomal studies as well as a micronucleus test were evaluated for each @entity1 . RESULTS: @entity1500 produced a significant @entity74 as proved by the increased incidence of chromosomal aberration and micronuclei formation in Group-III animals. Inversely, @entity4181 (group IV) produced a significant protection against @entity74 induced by @entity1500 . In @entity309 @entity1 , @entity4181 provides satisfactory improvement of @entity1500 -induced @entity74 . CONCLUSION: @entity4181 has a protective affect against @entity1500 genotoxicity in @entity1 as well as in animal models.

Protective effect of XXXX on low-dose @entity1499 genotoxicity.

@entity1 :: ('9606', 'Species') :: ['human', 'patients', 'patient'] @entity1501 :: ('MESH:D005492', 'Chemical') :: ['folate'] @entity4181 :: ('MESH:D002955', 'Chemical') :: ['Folinic acid', 'Leucovorin', 'folinic acid'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity1500 :: ('CHEBI:44185', 'Chemical') :: ['MTX'] @entity74 :: ('MESH:D030342', 'Disease') :: ['genetic damage', 'genetic injury', 'genetic damages'] @entity35 :: ('10116', 'Species') :: ['rat', 'Wistar', 'rats'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['Methotrexate'] @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis', 'RA']
@entity4181 :: (MESH:D002955,Chemical) :: ['folinic acid']
